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Abstract
Purpose
The immunogenicity of anti-TNF-α drugs may affect their safety and 
efficacy. Infliximab (IFX), a chimeric monoclonal antibody, induces 
antibody formation in up to 60 % of cases. Some studies have 
suggested the involvement of a Th1 response to TNFα blockers 
following immunization, but the triggering of Th17 responses has 
never been reported. The aim of this study is to investigate whether 
the immunogenicity of IFX affects the Th1, Th17 and Treg 
compartments in rheumatoid arthritis (RA) patients failing IFX 
therapy, and verify whether this may be responsible for treatment 
failure.
Methods
The study involved 55 patients with RA (15 treatment-naïve patients; 
20 IFX responders; 20 IFX non-responders) and 10 healthy controls. 
PBMCs were cultured in the presence/absence of IFX, and the 
variations in the percentage of Th1, Th17 and Treg lymphocytes 
following IFX treatment were analysed.
Results
IFX-specific Th1 and Th17 responses and an increase in IL-21 
production were observed in patients failing IFX (p < 0.01, p < 0.05, 
and p < 0.01 respectively). In contrast, IFX incubation reduced 
significantly Th1 and Th17 responses and IL-21 production (p < 0.05) 
in successfully-treated subjects, but did not affect these responses in 
healthy controls or treatment-naïve patients.
Conclusions
RA patients may have impaired peripheral tolerance, which could 
favour the development of an aberrant immunological response to 
biological drugs. The loss of therapeutic effectiveness of IFX and the 
Pagina 2 di 22e.Proofing
31/07/2015http://eproofing.springer.com/journals/printpage.php?token=HKll_RZyQ3BdgbzQnD...
onset of adverse events may be due to a paradoxical activation of 
Th17 or Th1 lymphocytes following sensitisation, thus worsening the 
patients’ inflammatory status.
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Introduction
Biological agents, a group of drugs obtained by means of recombinant 
DNA technology, include chimeric, humanised or fully human 
monoclonal antibodies, proteins or receptors capable of binding specific 
targets. In the field of rheumatology, their targets are usually molecules 
that play a crucial role in maintaining inflammation (e.g. TNFα or 
CD20). As their molecular structure contains a variable percentage of 
allogeneic components, they often elicit immunological responses 
associated with adverse events or a progressive lack of efficacy [ 1 ]. 
However, the immunogenicity of a biological agent also depends on its 
route of delivery, the degree of exposure, the frequency of 
administration, and the concomitant use of immunosuppressive agents. 
The humanisation of murine monoclonal antibodies has improved their 
tolerability, but even fully human antibodies may induce 
immunogenicity in a considerable number of patients probably because 
of anti-idiotype antibodies recognising the unique V region of other 
immunoglobulin molecules [ 2 ].
A number of clinical reports has recently investigated whether anti-
TNFα agents paradoxically activate the immune system because many 
autoimmune disorders have been reported during anti- TNFα treatment, 
including psoriasis, de novo developing arthritis, inflammatory bowel 
disease, sarcoidosis and demyelinating diseases [ 3 ].
Pagina 3 di 22e.Proofing
31/07/2015http://eproofing.springer.com/journals/printpage.php?token=HKll_RZyQ3BdgbzQnD...
Biological agents may be considered as antigens capable of activating 
adaptive immune responses when presented by dendritic cells to T 
lymphocytes. This might result in T lymphocytes differentiation into 
Th1, Th2, Th17 or Treg effectors, giving rise to different clinical 
situations. IgG, IgM and IgE antibodies against biological agents have 
been detected in the serum of patients with rheumatic diseases who 
were treated with these drugs [ 4–7 ], and seem to correlate with the 
likelihood of a progressive lack of efficacy or the development of 
adverse events [ 8 ]. Some case reports and histological studies [ 9 ] have 
also highlighted the involvement of Th1 responses following 
sensitisation to a TNFα blocker. However, to our knowledge, no 
elicitation of Th17 responses by TNFα blockers has been described yet.
The aim of this study was to investigate whether the immunogenicity of 
a biological agent may affect Th1 and Th17 responses and impair 
regulatory T cell activity. Due to its greater immunogenicity, IFX 
appeared the most suitable candidate among the TNFα blockers and was 
therefore chosen for our analyses.
Methods
Study Population
The study involved 55 patients with rheumatoid arthritis (RA) 
diagnosed on the basis of the EULAR/ACR 2010 criteria [ 10 ] and 10 
healthy controls. The patients included 20 consecutive adult male and 
female non-responders to IFX, who were compared with 15 treatment-
naïve patients and 20 matched patients successfully treated with IFX. 
Prednisone ≤5 mg/day was allowed provided that it had been 
administered at a stable dose for 4 weeks before blood sampling, as 
were methotrexate (at a maximum dose of 15 mg/week) [ 11 ], 
salazopyrin (at a maximum dose of 6 g/day) and hydroxychloroquine (at 
a maximum dose of 400 mg/day) provided that they had been 
administered at a stable dose for 6 weeks before blood withdrawal. The 
exclusion criteria were concomitant infections at the time of blood 
sampling, a vaccination in the previous 2 months [ 12 , 13 ], 
immunodeficiency, the concomitant use of leflunomide or cyclosporine 
[ 14–16 ], haematological disorders, and atopic dermatitis due to other 
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antigens. Table 1  shows the demographic characteristics of the study 
population.
Table 1
Demographic characteristics of the study population
Variables
Healthy 
controls
Treatment-
naïve
RA 
patients
RA 
patients 
responding 
to IFX
RA 
patients 
not 
responding 
to IFX
No. 10 15 20 20
Mean age ± SD, 
years
43.9 ± 
8.3
54.8 ± 16.2 61.3 ± 12.2 57.0 ± 12.2
Mean disease 
duration ± SD, years
/ 2.3 ± 3.9 13.4 ± 7.2 18.1 ± 9.5
F/M 4/6 12/3 16/4 15/5
ACPA + / 5 15 15
RF + / 7 11 15
ANA + / 2 12 17
Anti-dsDNA Ab+ / 0 3 2
Anti-ENA Ab+ / 0 1 3
ACLA/LAC + / 0 1 2
Prednisone (2.5
–10 mg/day)
/ / 8 14
Methotrexate (5
–15 mg/week)
/ / 20 9
Hydroxychloroquine 
(200–400 mg/day)
/ / 3 5
NSAIDs / 14 as needed as needed
SD standard deviation, F females, M males, ACPA anti-citrullinated-protein 
antibodies, RF rheumatoid factor, ANA anti-nuclear antibodies, anti-dsDNA
anti-double stranded DNA antibodies, anti-ENA anti-extractable nuclear 
antigen antibodies, ACLA anticardiolipin antibodies, LAC lupus 
anticoagulant, NSAIDs non-steroidal anti-inflammatory drugs
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The study was approved by our local Ethics Committee: the 
Institutional Review Board of Sacco Hospital (Milan, Italy); Protocol 
number: 364/2013 38AP; Deliberation number: 484. The study has been 
performed in accordance with the 1964 Declaration of Helsinki and its 
later amendments.
Written informed consent was obtained from all the patients.
Isolation and Culture of PBMCs
Peripheral blood was collected into Vacutainer tubes containing EDTA 
(Becton Dickinson; Rutherford, NJ, USA). PBMCs were isolated by 
centrifugation on lymphocyte separation medium (Cedarlane 
Laboratories, Burlington, NC, USA). The number and viability of 
PBMCs were determined by an automatic cell counter, ADAM-MC 
(Digital-Bio, NanoEnTek Inc., Corea). PBMC viability was typically > 
98 %.
Cell cultures were performed in RPMI 1640 plus Penicillin, 
Streptomycin, L-Glutamine and 10 % pooled Human AB Serum (all 
from Euroclone, Siziano, Italy). Fresh PBMCs, at a concentration of 1 × 
10  cells/mL were incubated for 18 h with culture medium alone or in 
the presence of 50 μg/mL IFX (Remicade, Janssen Biologics, Leiden, 
Netherlands), or 50 μg/mL Human IgG1kappa (Sigma-Aldrich, Saint 
Louis, Mo, USA), or 50 μg/mL recombinant Human IgG Fc (R&D 
Systems). PWM (Lectin from Phytolacca Americana; 1 μg/mL Sigma-
Aldrich), was used as a positive control to evaluate the responsiveness 
of PBMCs. To facilitate co-stimulation, 1 μg/mL anti-human CD28 
(R&D Systems) was added to the cell cultures. Brefeldin A (10 μg/mL; 
Sigma-Aldrich) was added after the first 3 h in to inhibit cytokine 
secretion.
Th1, Th17 and Treg Immune Responses
The percentage of Th1, Th17 and Treg lymphocytes was determined by 
flow cytometric analysis. Th1 lymphocytes were identified as IFNγ-, 
IL-2-secreting, Tbet-expressing CD4+ T cells; Th17 lymphocytes as IL-
17- , IL-21-secreting, RORγT-expressing CD4+ T cells; Treg 
lymphocytes as CD25 , FoxP3-expressing CD4+ T cells.
6
high
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The IFX concentration of 50 μg/mL was chosen after setting a titration 
test with increasing concentrations of the drug and on the basis of the 
IFX median serum concentrations 1 h after infusion (peak serum 
concentration: 39.9–219.1 μg) [ 17 ].
Flow Cytometry
The following monoclonal antibodies (mAbs) were used: CD4 PE-Cy7, 
IL-2 PE, CD25 ECD and IFNγ FITC (Beckman Coulter, Milan, Italy); 
Foxp3 PECy5, T-bet PerCP Cy5.5 and RORγT PE (eBiosciences, San 
Diego, CA, USA); IL-21 APC and IL-17A FITC (Biolegend, San 
Diego, CA, USA); TGFβ1 PE and IL-10 FITC (R&D Systems). PBMCs 
were incubated 15 min with the mAbs for the detection of cell surface 
antigens. Then cells were permeabilized 30 min with the 
Fixation/Permeabilization buffer (eBiosciences), and further stained 
with the antibodies for the detection of intracellular transcription factors 
and cytokines.
Lymphocyte population was gated based on the basis of forward and 
side scatter properties, and further gated for CD4 expression; at least 
20,000 events were acquired within the CD4 gate. The samples were 
acquired using a Gallios flow cytometer and data were analysed using 
Kaloosa software (both Beckman Coulter).
Statistical Analysis
As data were normally distributed, procedures were based on parametric 
analyses. Comparisons between the different groups were performed 
using unpaired Student’s T Test for unequal variances with a two tailed 
P value. Significance was set at P < 0.05. Statistical analysis was 
performed using GraphPad Prism Software (GraphPad Software, San 
Diego, CA, USA).
Results
Patient Demographic and Clinical Details
We enrolled 20 consecutive RA patients (16 females; mean age 61.3 ± 
12.2 years; mean disease duration 13.4 ± 7.2 years) successfully treated 
with IFX 3 mg/kg every 8 weeks, and 20 consecutive RA patients (15 
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females; mean age 57.0 ± 12.2 years; mean disease duration 18.1 ± 
9.5 years) who discontinued IFX due to inefficacy (11 cases) or adverse 
events (9 cases). A total of 15 patients were positive for anti-
citrullinated protein antibodies (ACPAs), and 11 responders and 15 
non-responders were positive for rheumatoid factor (RF). During IFX 
treatment, anti-nuclear antibodies (ANAs) appeared in 12 responders 
and 17 non-responders (Table 1 ). No clinical correlations were found. 
The IFX non-responders were treated with abatacept 10 mg/kg every 
4 weeks (13 subjects), tocilizumab 8 mg/kg every 4 weeks (5 subjects), 
etanercept 50 mg once a week (1 subject), or certolizumab pegol 
200 mg every other week (1 subject) as the second (8 subjects), third (8 
subjects), or fourth biological agent (4 subjects). The patients in both 
treated groups concomitantly received the allowed Disease-modifying 
antirheumatic drugs (DMARDs) and corticosteroids.
Th1 and Th17
In order to evaluate whether the immunogenic effects of IFX are 
mediated by Th1 and Th17 lymphocytes, these subpopulations were 
analysed in RA patient groups (treatment-naïve, IFX responders, IFX 
non-responders) and in healthy controls, under unstimulated and IFX-
stimulated conditions.
Under unstimulated conditions, the percentage of both IFNγ-secreting, 
Tbet-expressing, CD4+ T cells and IL-2-secreting, Tbet-expressing, 
CD4+ T cells was significantly lower in healthy controls than in RA 
patient groups. Furthermore, there was a significantly higher proportion 
of IFNγ- and IL-2-secreting Th1 cells in naïve RA patients compared to 
both IFX-responders and non-responders (Fig. 1a, b ). Th17 
lymphocytes (IL-17-secreting, RORγT-expressing CD4+ T cells) 
showed a similar trend, being significantly higher in RA patients than in 
healthy subjects, and significantly higher in naïve patients than in IFX 
responders (P < 0.05) (Fig. 1c ).
Fig. 1
Percentages of Th1 and Th17 subpopulations under unstimulated, 
IgG1kappa-stimulated, and IFX-stimulated conditions in RA patients and 
healthy controls. Th1 lymphocytes were identified as IFNγ- (a) or IL2-
producing, T-bet-expressing, CD4+ T cells (b), and Th17 lymphocytes as 
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IL17- (c) or IL21-producing, RorγT-expressing CD4+ T cells (d). The 
frequency of each subset of CD4+ T cells was compared among healthy 
controls (n = 10), treatment-naïve (n = 15), IFX responders (n = 10), and 
IFX non-responders (n = 20). Results are shown as Box and Whisker Plot 
(Tukey’s method). *p < 0.05; ** p < 0.01 (Student’s t test)
As IL-21 plays an important role in Th17 differentiation and expansion 
by amplifying Th17 responses, we evaluated the production of this 
cytokine by Th17 cells.
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As expected, healthy controls had the lowest percentage of IL-21-
secreting, RORγT-expressing CD4+ T cells and treatment-naïve RA 
patients were characterized by a significantly higher percentage of these 
cells than IFX responders (P < 0.01) (Fig. 1d ).
The IFX stimulation of PBMCs from the three groups of RA patients 
and healthy controls led to completely different immune profiles, with 
the IFX non-responders developing IFX-specific Th1-Th17 responses.
IFX stimulation significantly increased both IFNγ-secreting, Tbet-
expressing CD4+ T cells and IL-2-secreting, Tbet-expressing CD4+ T 
cells in non-responder patients (P < 0.01), but significantly diminished 
these cells (P < 0.05) in responder patients compared to unstimulated 
condition. In contrast, no significant differences were detected in 
healthy individuals and in naïve patients, even if a trend in the reduction 
of Th1 lymphocytes was observed in naïve patients (Fig. 1a, b ).
Similarly, IL17- and IL21-secreting, RORγT-expressing CD4+ T cells 
in IFX treated cultures were significantly augmented in non-responders 
and decreased in responders compared to unstimulated conditions (P < 
0.05, in both the cases); on the contrary, no significant variations were 
seen in naïve patients and healthy individuals (Fig. 1c, d ).
Addition of non-specific human IgG belonging to the same isotype of 
IFX (IgG1 kappa) did not alter the percentage of Th1 and Th17 
subpopulations in any of the groups, suggesting that the effects reported 
were IFX-specific (Fig. 1a, b, c, d ).
Finally, we verified whether the increase in Th1 and Th17 responses 
correlated with the onset of adverse events or the inefficacy of IFX 
therapy in IFX non-responders. We observed that the percentage of 
IL17-secreting, RORγT-expressing CD4+ T cells was significantly 
higher in the patients who discontinued therapy because of inefficacy 
than in those who discontinued it because of adverse events, under both 
unstimulated and IFX-stimulated conditions (P < 0.05 and P < 0.01; 
Fig. 2 ). On the contrary, there was no correlation between 
discontinuation for inefficacy or adverse effects and the increase in the 
percentage of Th1 lymphocytes (not shown).
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Fig. 2
Percentages of Th17 T lymphocytes (IL17, RorγT-expressing CD4+ T 
cells) under unstimulated, IgG1kappa-stimulated, and IFX-stimulated 
conditions in the IFX non-responder patients who discontinued therapy 
because of inefficacy (n = 11) or adverse effects (N = 9). Results are 
shown as Box and Whisker Plot (Tukey’s method). *p < 0.05; **p < 0.01 
(Student’s t test)
Treg
As the number and functionality of Treg cells are altered in RA 
patients, we investigated the effect of IFX treatment on this T cell 
subset. Under unstimulated conditions, the percentage of CD25 , 
FoxP3-expressing CD4+ T cells was higher in healthy controls than in 
treatment-naïve and IFX non-responders patients (P < 0.01 in both the 
cases). Moreover, these cells were increased in IFX-responders 
compared to treatment-naïve patients (P < 0.01) and IFX non-
responders (P < 0.05). Instead, no statistically significant difference was 
observed between healthy controls and responders (Fig. 3a ).
Fig. 3
Regulatory T lymphocytes under unstimulated, IgG1kappa-stimulated, 
and IFX-stimulated conditions in RA patients and healthy controls. a
shows the percentage of total Treg lymphocytes, b the percentage of 
TGFβ-producing Treg lymphocytes, and c the percentage of IL-10-
producing Treg lymphocytes. The frequency of Tregs, IL-10-producing 
Tregs, and TGFβ-producing Tregs was compared among healthy controls 
(n = 10), treatment-naïve (n = 15), IFX responders (n = 10), and IFX non-
high
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responders (n = 20). Results are shown as Box and Whisker Plot (Tukey’s 
method). *p < 0.05; **p < 0.01 (Student’s t test)
The exposure of PBMCs to IFX led to a significant reduction in Treg 
cells compared to unstimulated condition only in the samples taken 
from non-responders (P < 0.05). As TGFβ and IL-10 mediate the 
suppressive action of Tregs, we evaluated their production by Tregs 
after IFX exposure in all the groups. IFX significantly reduced the 
levels of TGFβ-producing Treg cells in non-responders (P < 0.05) and 
increased them in responders (P < 0.05), compared to unstimulated 
conditions; no difference in the number of Treg cells or in the frequency 
of TGFβ-secreting Tregs was observed in the IFX-stimulated PBMCs of 
treatment-naïve patients or healthy controls (Fig. 3b ). Furthermore, 
there was no change in the frequency of IL10-secreting Tregs in any of 
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the groups (Fig. 3c ). The addition of non-specific human IgG did not 
alter the percentage of Tregs, TGFβ-producing Tregs, or IL10-
producing Tregs in any of the groups (Fig. 3a, b, c ).
Th17/Treg Ratio
Alterations in the Th17/Treg ratio have been reported in RA patients 
and, under unstimulated conditions, we found that the ratio was 
significantly higher in all of the patient groups than in healthy controls. 
Furthermore, both naïve and non responder patients showed a 
significantly higher Th17/Treg ratio than IFX responders. Upon 
Infliximab stimulation, the Th17/Treg ratio significantly increased in 
non-responders and decreased in responders, compared to unstimulated 
or IgG1kappa-stimulated conditions. In both healthy subjects and in 
naïve patients a trend in increase of the Th17/Treg ratio was observed, 
but statistical significance was not reached (Fig. 4 ).
Fig. 4
Th17/Treg ratio under unstimulated, IgG1kappa-stimulated, and IFX-
stimulated conditions in RA patients and healthy controls. The ratio was 
compared among healthy controls (n = 10), treatment-naïve (n = 15), IFX 
responders (n = 10), and IFX non-responders (n = 20). Data represent 
mean ± SE. *p < 0.05; **p < 0.01 (Student’s t test)
Discussion
Biological drugs can behave as antigens and be presented via the MHC 
II complex, inducing the differentiation of naïve T cells into Th1, Th2 
or Th17 lymphocytes depending on the cytokine microenvironment [ 18 , 
19 ]. A lack of immunological tolerance (a distinctive trait of 
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autoimmune diseases) may contribute to the expansion of the Th17 cell 
compartment, and it can be hypothesised that the breakdown of 
peripheral tolerance during rheumatic diseases shifts immunological 
responses towards a Th17 profile.
Antibodies reacting against biological agents have been found in the 
serum of rheumatic patients failing biological therapy. The antibodies 
produced may belong to different isotypic classes (IgM, IgG, and IgE), 
thus activating different immunological effector pathways [ 6 , 20 ].
Among TNFα blockers, IFX (a chimeric monoclonal antibody 
containing 25 % of mouse-derived proteins) induces the formation of 
anti IFX antibodies in a high percentage of the patients treated with this 
drug [ 21 ], whereas adalimumab and etanercept are less immunogenic 
because of their different molecular structures and administration routes 
[ 22 ]. The concomitant use of traditional DMARDs is recommended 
during anti-TNF therapy because it reduces the immunogenicity of all 
biological drugs [ 23 ].
However, very little is known about the activation of an adaptive 
response involving Th1 or Th17 lymphocytes by TNFα blockers. The 
published data are conflicting possibly because they relate to different 
patient populations, cell culture conditions and methodologies.
Given the still limited knowledge of the immunogenicity of anti-TNF 
drugs, we studied Th1, Th17 and Treg responses in different subsets of 
RA patients (patients discontinuing IFX treatment because of 
ineffectiveness or clearly drug-related adverse events, IFX responders, 
and treatment-free RA patients) and healthy controls.
We found that treatment-naïve RA patients have a higher percentage of 
Th1 and Th17 lymphocytes than healthy donors, which is in line with 
the findings of various studies suggesting that these cells contribute to 
the pathophysiology of the disease [ 24–27 ]. Moreover, the percentage 
of Th1 and Th17 lymphocytes was significantly greater in treatment-
naïve RA patients than in IFX-responders.
A recent study on IFX-treated RA patients found a greater reduction in 
the chemokines belonging to the Th1 than to the Th2 axis [ 28 ]. Other 
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authors have instead observed that a 6 weeks’ treatment increases the 
IFNγ/IL-4 ratio in IFX responders, but does not seem to affect the 
Th1/Th2 ratio in non-responder patients [ 29 ]. However, in the latter 
study the Th1 and Th2 responses were examined after prolonged culture 
of PBMCs in presence of Th1 polarising cytokines, such as IL-12 and 
IL-18. On the other hand, the treatment with other biological agents 
(adalimumab and etanercept) was reported to significantly decrease the 
percentage of Th1 and Th17 cells in comparison with pre-treatment 
levels [ 24 , 26 , 30 ].
Upon IFX stimulation, we observed a significant increase in the 
percentage of Th1 and Th17 lymphocytes in non-responder patients, 
compared to unstimulated condition. Interestingly, IFX induced IL-21 
production by Th17 cells in non-responders. This cytokine plays an 
important role in RA, as it is found at high levels in synovial fluid and 
serum of RA patients and significantly stimulates Th17 proliferation 
[ 31 ]. On the contrary, incubation with IFX repressed Th1 and Th17 
responses in IFX responders, but did not significantly affect these 
responses in healthy controls or treatment-naïve patients (although there 
was a trend towards a reduction in Th1 responses in naïve patients).
A study has reported that, in healthy subjects, IFX suppresses Th1 
responses more markedly than Th17 response. However, in this study 
CD4 T lymphocytes from healthy subjects were cultured under 
polarizing conditions that specifically induced Th1 or Th17 
differentiation [ 32 ].
The increase in Th1 responses was not significantly associated with 
either inefficacy or adverse events, but the patients who discontinued 
IFX because of inefficacy showed a significantly greater increase in 
Th17 responses than those who discontinued the therapy because of 
adverse events.
The results obtained suggested that IFX may induce the paradoxical 
activation of Th1 and Th17 responses in IFX non-responders.
We also investigated whether an impairment of Treg lymphocytes may 
contribute, at least in part, to activation of Th1 and Th17 responses 
induced by IFX treatment. Several studies on RA patients have reported 
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alterations in the frequency and functioning of Treg cells, as well as in 
the Th17/Treg balance. The proportion of Tregs in peripheral blood of 
early active RA patients prior to disease modifying treatment is smaller 
than in healthy controls and also their suppressive functions are altered. 
Furthermore, anti-rheumatic biological therapy (including IFX therapy) 
can increase the proportion of Tregs, restore their functions, and shift 
the Th17/Treg balance in favour of Tregs [ 24 , 33–36 ]. In agreement 
with these studies, we observed a significantly lower percentage of 
Tregs and TGFβ-secreting Treg in naïve patients than in healthy 
controls and an increased percentage of these subpopulation in IFX-
responders compared to naïve and non-responder subjects. In addition, 
the exposure to IFX of PBMCs from non-responders further decreased 
Treg frequency and TGFβ secretion. IFX restored the Th17/Treg 
balance in favour of Tregs in responders, whereas in non- responders 
the Th17/Treg ratio was even increased. There was therefore an inverse 
correlation between the percentage of Tregs and the percentage of Th1 
and Th17 cells.
Accumulating evidence suggests the reciprocal cross-regulation of Th17 
and Tregs by means of different regulatory mechanisms [ 37 ], and a 
subset of Tregs able to convert into pathogenic Th17 lymphocytes under 
inflammatory conditions has recently been identified [ 38 ]. Further 
studies are necessary to better elucidate the effect of IFX on Treg/Th17 
balance.
Conclusions
A considerable number of RA patients gains no benefit or experiences 
adverse events after starting anti-TNFα therapy. The economic burden 
of prescribing potentially dangerous or unnecessary treatments 
prompted us to study the mechanisms responsible for treatment failure. 
Subjects with autoimmune diseases such as RA have impaired 
peripheral tolerance, which could favour the development of an aberrant 
immunological response against a wide range of antigens, and the 
findings of this in vitro study indicate that IFX may activate aberrant 
immunological responses in non-responders to IFX treatment. The 
development of Th1 or Th17 responses following sensitisation to 
biological agents may even worsen the inflammation related to the 
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underlying disease, and further studies of the Th cell network could 
improve our understanding of the role of anti-TNF agents in 
unbalancing the immune system of RA patients.
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